RxTROSPECT ANALYTICS
Access drug approval data,
see health authority decisions
Trusted by well
respected companies
Stop Google searching for regulatory precedent
rapid answers to urgent needs
RxTROSPECT excels at identifying the key information that guided regulatory decisions by the FDA and EMA. This allows users to quickly access crucial data across various products that have been approved in oncology.
As a result, it significantly enhances the development of effective regulatory strategies and provides valuable insights for anyone seeking to understand how leading regulatory bodies approve drugs and the rationale behind their decisions.
RxTROSPECT offers a comprehensive intelligence platform for understanding FDA and EMA regulatory decisions. It can be used independently or integrated with existing subscription services and publicly available data sources to create a complete intelligence ecosystem.
Complementary solution,
not competing tech
integrated analytics solution
See approval precedent in Europe and the United States
Choose what’s best for you
Base option
Best for small local teams — Under 10 people
Our entry-level option is suitable for our smaller biotech customers and those with local teams. It equips staff with analytics on decisions made by the United States FDA and European Medicines Agency.
Enhance performance of small teams with turn-key analytics
Rapidly identify regulatory precedent on product approvals
Growing teams add users with single license procurement
scaled option
Best for global teams — Over 10 people
Customers that subscribe to 10 users, will receive 25 users total. The key benefit is it gives managers the flexibility to move fast and scale access without the hassle of doing single-license procurement.
Access 25 users instantly and significantly reduce price per user
Give new hires instant access without waiting for procurement
Scale access globally and manage permissions with agility
GET STARTED
Navigate your optimal approval pathway
Here’s what
people are asking
-
Depending on your company’s procurement process, we can get you access as quickly as we receive a Purchase Order. Your team can expect access within 7 days of receiving a PO.
The typical steps are:
Customer: Request quote
RxTROSPECT: Send quote
Customer: Create Purchase Order (PO)
RxTROSPECT: Send invoice (with PO # if applicable)
Customer: Provide user details (N/A for renewal)
RxTROSPECT: Give authorized users access to tech
-
Our system is updated within 48 hours of health authority approvals. The scope of our products include the decisions made by the top two global health authorities, the United States FDA and European Medicines Agency.
-
You will receive instructions to create login credentials from our chosen partner, Tableau. Those subscribed to our Base Option are required to use Multi-Factor Authentication (MFA) to login, while those subscribed to our Scaled Option may login directly without the need for MFA.
Our partnership with Tableau ensures our analytics products are reliably delivered.

rxtrospect analytics
The #1 digital solution for
Digital Regulatory Strategists
This core product offering was purposefully designed with an understanding of the end-user’s role. This means that we get what it means to investigate prior drug approvals in order to inform an optimal approval strategy for a NDA/BLA. Our users appreciate this and their feedback has steered our platform enhancements, which have been continuously improved.
We know what is being asked of the people in regulatory roles and have uniquely built a solution that they value.